Clinical validation of the Tempus xO assay

Oncotarget. 2018 May 25;9(40):25826-25832. doi: 10.18632/oncotarget.25381.


We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by the assay. We also demonstrate highly accurate copy number measurements and gene rearrangement identification.

Keywords: Tempus; cancer; gene panel; genomic test; transcriptome.